No Data
No Data
No Data
No Data
No Data
323 drugs, hurry up! America is facing the biggest “drug shortage” in history...
The US now seems to be facing an unprecedented “drug shortage”...
cls.cnApr 15 14:37
Durect Price Target Maintained With a $5.00/Share by Oppenheimer
Durect Price Target Maintained With a $5.00/Share by Oppenheimer
Dow JonesApr 1 21:29
Oppenheimer Reiterates Outperform on Durect, Maintains $5 Price Target
Oppenheimer analyst Francois Brisebois reiterates Durect (NASDAQ:DRRX) with a Outperform and maintains $5 price target.
BenzingaApr 1 21:19
HC Wainwright & Co. Reiterates Neutral on Durect
HC Wainwright & Co. analyst Ed Arce reiterates Durect (NASDAQ:DRRX) with a Neutral.
BenzingaMar 28 20:11
Durect Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/28/2024 — HC Wainwright & Co. Reiterates → Neutral 11/09/2023 — JonesTrading Downgrades Buy → Hold 11
BenzingaMar 28 20:08
Earnings Call Summary | Durect(DRRX.US) Q4 2023 Earnings Conference
The following is a summary of the DURECT Corporation (DRRX) Q4 2023 Earnings Call Transcript:Financial Performance:DURECT reported total revenues of $8.5 million in 2023, significantly lower than the
Futu NewsMar 28 06:17 · Conference Call
No Data
No Data